HSIC

Business Profile & Competitive Position

Henry Schein, Inc. operates in the Healthcare sector under the Medical – Distribution industry. It describes itself as a health care solutions company serving primarily office-based dental and medical practitioners, plus alternate sites of care, through three reportable segments. The Global Distribution and Value-Added Services segment supplies dental and medical merchandise, equipment, repair services, pharmaceuticals, vaccines, and value-added services. The Global Specialty Products segment manufactures and markets dental implants, biomaterials, endodontic, orthodontic, and orthopedic products. The Global Technology segment develops and distributes practice-management software, e-services, and other technology-enabled products for health care providers.

The company’s physical footprint is substantial: 38 distribution centers covering more than 5.4 million square feet, 17 manufacturing facilities covering 0.6 million square feet, an average shipment volume of approximately 150,000 cartons daily, and 127 equipment sales and service centers worldwide. That scale supports a stocked selection of more than 300,000 products.

Margin and return data show what kind of business this scale creates. Henry Schein’s net margin is 3.0% and its ROE is 12.4%. The low net margin is consistent with a distribution-heavy model in which profit is earned through high inventory turnover rather than wide pricing power. The mid-teens ROE suggests management is generating reasonable returns on shareholder equity, but the narrow margin also means the moat is largely operational—network density, logistics efficiency, customer relationships, and breadth of SKU coverage—rather than a high-margin brand or patent advantage.

Financial Posture

Henry Schein currently carries a market capitalization of $9.4 billion and trades at a P/E ratio of 24.4. That multiple places the stock at a premium to many traditional industrial distributors and reflects the healthcare end-market’s perceived stability, even though profitability per dollar of revenue is thin. The beta of 0.84 indicates lower sensitivity to broad equity-market swings than the average stock, which fits a defensive, non-cyclical distribution business.

The latest price snapshot shows HSIC at $84.48, with an RSI of 45.2 and the 50-day EMA at $85.92. The price sits just below its 50-day exponential moving average and the RSI is near neutral, neither overbought nor oversold. Combined with a 3.0% net margin and 12.4% ROE, the valuation picture is one of a steady, low-growth-momentum distributor valued for reliability rather than explosive expansion.

Strategic Priorities & Outlook

In its most recent 10-K filing, Henry Schein outlined several operational priorities. The headline initiative is the BOLD+1 strategic plan, which aims to build complementary software, specialty, and services businesses for higher growth. Running alongside that is “One Distribution,” a program to deliver an exceptional customer experience while increasing efficiency and driving growth, and “One Schein,” which is designed to broaden and deepen relationships with customers across the company’s segments. The filing also emphasizes a push to drive digital transformation both for customers and internally.

Some concrete operational metrics illustrate the scale those priorities must move. The technology segment had an active user base of approximately 95,000 practices and 324,000 consumers as of December 27, 2025. That installed base gives Henry Schein a recurring touchpoint with practitioners and is a logical foundation for the software and services growth targeted under BOLD+1. The strategic challenge is converting that customer density into faster-growing, higher-margin revenue streams without disrupting the core distribution cash flow.

Macro & Geopolitical Exposure

As a medical distributor, Henry Schein is exposed to the macro and regulatory forces that shape health care delivery and global trade. Because the company distributes pharmaceuticals, vaccines, and medical devices, it faces ongoing FDA and health-regulatory compliance requirements across its product lines. Changes in health care reimbursement policy, including Medicare, Medicaid, and dental-plan coverage, can influence office-based practitioner volumes and therefore demand for supplies, equipment, and technology.

The company also has meaningful global supply-chain exposure. With 17 manufacturing facilities plus sourcing for 300,000 SKUs, tariffs, trade restrictions, or currency swings can affect input costs and pricing. Freight, fuel, and logistics costs matter to a business shipping roughly 150,000 cartons daily. In addition, demand for vaccines and infection-control products can move with public-health cycles, while pricing pressure in generics and pharmaceuticals is a persistent feature of drug distribution. All of these are industry-level risks implied by the Medical – Distribution classification, not company-specific forecasts.

Recent Developments

Recent headlines show Henry Schein drawing attention from both growth and value lenses. On October 19, 2026, Zacks published “Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term.” A few days earlier, on October 14, 2026, Zacks ran “Henry Schein (HSIC) is a Top-Ranked Value Stock: Should You Buy?” On October 6, 2026, Zacks also compared HSIC directly with Merit Medical Systems (MMSI) in “HSIC or MMSI: Which Is the Better Value Stock Right Now?” That clustering of growth-versus-value commentary simply reflects a stock with mixed valuation signals, not a directional verdict.

The most operationally significant news came on October 8, 2026, when Henry Schein announced a Chief Financial Officer leadership transition via Business Wire. A CFO change can affect investor confidence around guidance, capital allocation communication, and execution of the BOLD+1 plan, particularly with the next earnings report approaching.

Earnings Behavior & Post-Earnings Drift

Henry Schein’s earnings record has been solid in terms of beats. Over the last eight reported quarters, the company has beaten estimates 6 out of 8 times, for a 75% beat rate, with an average earnings surprise of 2.9%. Yet the stock’s behavior after those beats has been inconsistent and, on average, negative. Across those same eight quarters, the average 5-day price move after earnings was −2.05%, classified as a downward post-earnings drift.

The most recent four quarters illustrate that tension. On August 4, 2026, HSIC reported EPS of $1.27 versus an estimate of $1.24 (a 2.4% beat); the stock rose 0.54% the next day and 0.08% over the following five days. The previous quarter, on May 5, 2026, EPS came in at $1.32 against a $1.20 estimate, a 10% surprise, yet the stock fell 2.6% the next day and 6.75% over the next five sessions. On February 24, 2026, a 3.1% beat ($1.34 reported vs. $1.30 estimated) led to a −1.73% next-day move and a −3.77% five-day move. The beat on November 4, 2025 was an 8.7% positive surprise ($1.38 vs. $1.27), supporting a 0.56% next-day gain and a 2.25% five-day gain.

The pattern suggests that headline EPS beats are not always enough to sustain the stock. The market’s real expectation likely hinges on guidance, margin commentary, and segment momentum. Looking ahead, Henry Schein is scheduled to report next on November 3, 2026, before the market open, with a current consensus EPS estimate of $1.36.

For a deeper dive into how institutional analysts are interpreting Henry Schein’s valuation, margin trajectory, and upcoming earnings setup, it is worth reviewing the full institutional verdict rather than relying solely on headline beat rates.